Printer Friendly
The Free Library
19,122,084 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Over the Last Decade Drug Price Cuts and Increasing Patient Co-payment Levels Have Been Key to Containing Pharmaceutical Expenditure in Japan.


DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49737) has announced the addition of Datamonitor's new report: Pricing and Reimbursement Reimbursement

Payment made to someone for out-of-pocket expenses has incurred.
 in Japan: Costly Healthcare System Inefficiencies increase the focus on healthcare cost containment cost containment,
n the features of a dental benefits program or of the administration of the program designed to reduce or eliminate certain charges to the plan.
 to their offering.

The government has relied on simple P&R tools to contain rising healthcare costs and provide a reasonable level of healthcare. However, factors such as a healthier elderly population are masking mask·ing
n.
1. The concealment or the screening of one sensory process or sensation by another.

2. An opaque covering used to camouflage the metal parts of a prosthesis.
 healthcare system inefficiencies, boosting healthcare costs and increasing the focus on cost containment. Although the rise in drug spending is slowing down, it remains a visible cost containment target.

Scope of this title:

- Overview of the Japanese healthcare system, detailing trends shaping healthcare provision including how P&R fits in

- In-depth analysis of the Japanese P&R infrastructure, examining how P&R tools are used to contain costs

- Examination of macro trends shaping healthcare provision and the P&R environment

- Identification of future trends shaping P&R tool use and healthcare evolution in Japan

Highlights of this title:

Over the last decade, biennial biennial, plant requiring two years to complete its life cycle, as distinguished from an annual or a perennial. In the first year a biennial usually produces a rosette of leaves (e.g., the cabbage) and a fleshy root, which acts as a food reserve over the winter.  drug price cuts and increasing patient co-payment co-payment Managed Care That portion of a claim or medical expense that a health plan member must pay out-of-pocket for specific medical services–eg, hospital care, drugs, office visits, etc; the insurer pays the remaining portion  levels have been the key tools used to contain pharmaceutical expenditure.

In the future, a range of factors will impact the P&R environment, including greater generic uptake uptake /up·take/ (up´tak) absorption and incorporation of a substance by living tissue.

up·take
n.
, the wider adoption of a prospective payment reimbursement system, and determining a solution to providing the elderly with adequate yet cost effective healthcare provision.

A range of macro trends are also impacting drug prescription and P&R, including: rising healthcare costs as a result of system inefficiencies, the fact that innovation is neither well-cultivated by Japanese drug developers nor well-rewarded by the Japanese government, and lastly the effects of an ageing population combined with a stagnant stagnant /stag·nant/ (stag´nant)
1. motionless; not flowing or moving.

2. inactive; not developing or progressing.
 economy.

Reasons to order your copy:

- Gain a clear understanding of the healthcare market dynamics and factors influencing healthcare provision in Japan

- Understand the role of different P&R tools in healthcare cost containment in Japan

- Gain insight into how P&R and more global macro The term global macro is used to classify the strategy of certain hedge funds—those that take large leveraged positions in financial derivatives, on the basis of forecasts about interest rate trends, movements in the general flow of funds, political changes, government  trends are set to shape healthcare provision in the future

For more information visit http://www.researchandmarkets.com/reports/c49737

Source: Datamonitor
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 5, 2007
Words:351
Previous Article:James Monroe Capital Progress Report.
Next Article:Qpixel Technology Opens Office in Japan.
Topics:



Related Articles
Drug utilization: what is to be done?
The medical benefits audit.
Goddamn the Pusher Man.
PRESCRIPTION FOR TROUBLE : Why drug prices keep exploding.
Shaking up the drug industry. (Trends).
Assessing consumer gains from a drug price control policy in the United States.
Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484.
Chugai to Launch HIV Protease Inhibitor INVIRASE(R) Tablet 500mg on September 15.
Chugai Pharmaceutical to Establish an Oncology Unit.
Shionogi Launches Cancer Pain Analgesic OxiNorm Powder 0.5% in Japan.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles